SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : General market lab and commentary
SPY 670.97+0.1%Nov 7 4:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Robohogs who wrote (380)5/27/2016 7:15:44 AM
From: The Ox  Read Replies (1) of 668
 
VRX may be a good longer term short. Everyone thinks it gets back higher. I doubt it. Debt. Debt. Debt. No growth.
Valeant Pharmaceuticals moved sharply higher in after-hours trading on a report tipping that Takeda ( OTCPK:TKPYY) and private equity firm TPG made a combined takeover approach in recent weeks that the company rejected. The approach came before Valeant (NYSE: VRX) hired Joseph Papa as its new CEO. Papa is expected to be given time by the board to chart a course for the specialty pharmaceutical and medical devices firm.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News